Analysts upgraded C4 Therapeutics' revenue forecasts, predicting a 3.1% decline in sales in 2024. Despite reduced losses and improved revenue outlook, the consensus price target fell 14%. The company is moving towards profitability, but faces challenges compared to industry peers.